27 results
253G3
STSS
Sharps Technology Inc
4 Jun 24
Offering circular supplement
5:03pm
our inception in 2017 and through the fourth quarter of 2022, we have devoted substantially all of our resources to the research and development … for the three months ended March 31, 2024. Substantially all of our net losses resulted from costs incurred in connection with our research and development
8-K
EX-99.1
b16uohyg zlu1kaa
28 Sep 23
Regulation FD Disclosure
11:27am
8-K
EX-10.1
fpehw0 8x8ocn1r
26 Sep 23
Signed term sheet providing for up to $75 Million in debt financing to be used for the acquisition
8:45am
424B4
8kvq0h3gv
25 Apr 23
Prospectus supplement with pricing info
4:15pm
10-K
dcmsjix
31 Mar 23
Annual report
4:17pm
8-K
EX-99.1
f7mnizwb6yhobn8
10 Nov 22
Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. Announce
4:06pm
8-K
uddq3
14 Jul 22
Sharps Technology Completes Acquisition of Safegard Medical Syringe Manufacturing Facility
4:05pm
8-K
EX-99.1
qp4ym k2x6u3d2l80h
14 Jul 22
Sharps Technology Completes Acquisition of Safegard Medical Syringe Manufacturing Facility
4:05pm
10-Q
7ayztsx
25 May 22
Quarterly report
5:29pm
424B4
1tc9oxf
15 Apr 22
Prospectus supplement with pricing info
4:48pm